Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
665.51 x 1 671.28 x 1
Post-market by (Cboe BZX)
665.46 -24.90 (-3.61%) 02/11/25 [NASDAQ]
665.51 x 1 671.28 x 1
Post-market 667.40 +1.94 (+0.29%) 16:25 ET
News & Headlines for Tue, Feb 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Regeneron Announces Investor Conference Presentations

REGN : 665.46 (-3.61%)
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

REGN : 665.46 (-3.61%)
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities....

CRSP : 39.62 (+0.53%)
REGN : 665.46 (-3.61%)
AMGN : 296.66 (+0.63%)
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

INCY : 66.33 (-2.88%)
ABBV : 191.83 (+0.78%)
REGN : 665.46 (-3.61%)
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

REGN : 665.46 (-3.61%)
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

REGN : 665.46 (-3.61%)
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page

The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug.

QQQ : 527.99 (-0.24%)
XLV : 146.03 (-0.18%)
REGN : 665.46 (-3.61%)
SPY : 605.31 (+0.08%)
Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

PYPL : 76.21 (-2.59%)
UBS : 33.16 (-1.34%)
J : 133.22 (-0.87%)
REGN : 665.46 (-3.61%)
Company News for Feb 5, 2025

Ferrari N.V.’s (RACE) shares jumped 7.1% after the company reported fourth-quarter 2024 adjusted earnings per share of $2.28, surpassing the Zacks Consensus Estimate of $1.89.Shares of Regeneron Pharmaceuticals...

WEC : 102.70 (+1.46%)
RACE : 474.96 (+3.07%)
MPLX : 53.18 (-0.73%)
REGN : 665.46 (-3.61%)
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and full-year...

REGN : 665.46 (-3.61%)
SNY : 53.90 (+1.16%)

Barchart Exclusives

Is Cotton Cheap at Below 70 Cents per Pound?
Cotton futures reached an eleven-year high of over $1.50 per pound in 2022 but ran out of upside steam. They last traded above $1 in March 2024 before falling under the 70 cents per pound level. As the cotton market heads into the 2025 crop year, the price is at an attractive level that could have significant upside potential. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Optimizing Trade Entries with the Futures Trading Guide